Literature DB >> 10593973

The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin.

J W Thomas1, M A Cooley, J M Broome, R Salgia, J D Griffin, C R Lombardo, M D Schaller.   

Abstract

Focal adhesion kinase (FAK) and paxillin are focal adhesion-associated, phosphotyrosine-containing proteins that physically interact. A previous study has demonstrated that paxillin contains two binding sites for FAK. We have further characterized these two binding sites and have demonstrated that the binding affinity of the carboxyl-terminal domain of FAK is the same for each of the two binding sites. The presence of both binding sites increases the affinity for FAK by 5-10-fold. A conserved paxillin sequence called the LD motif has been implicated in FAK binding. We show that mutations in the LD motifs in both FAK-binding sites are required to dramatically impair FAK binding in vitro. A paxillin mutant containing point mutations in both FAK-binding sites was characterized. The mutant exhibited reduced levels of phosphotyrosine relative to wild type paxillin in subconfluent cells growing in culture, following cell adhesion to fibronectin and in src-transformed fibroblasts. These results suggest that paxillin must bind FAK for maximal phosphorylation in response to cell adhesion and that FAK may function to direct tyrosine phosphorylation of paxillin in the process of transformation by the src oncogene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593973     DOI: 10.1074/jbc.274.51.36684

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Molecular recognition of leucine-aspartate repeat (LD) motifs by the focal adhesion targeting homology domain of cerebral cavernous malformation 3 (CCM3).

Authors:  Xiaofeng Li; Weidong Ji; Rong Zhang; Ewa Folta-Stogniew; Wang Min; Titus J Boggon
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

2.  FERM domain interaction promotes FAK signaling.

Authors:  Jill M Dunty; Veronica Gabarra-Niecko; Michelle L King; Derek F J Ceccarelli; Michael J Eck; Michael D Schaller
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

3.  FAK potentiates Rac1 activation and localization to matrix adhesion sites: a role for betaPIX.

Authors:  Fumin Chang; Christopher A Lemmon; Dongeun Park; Lewis H Romer
Journal:  Mol Biol Cell       Date:  2006-11-08       Impact factor: 4.138

Review 4.  Significance of talin in cancer progression and metastasis.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

5.  Structural basis for the autoinhibition of focal adhesion kinase.

Authors:  Daniel Lietha; Xinming Cai; Derek F J Ceccarelli; Yiqun Li; Michael D Schaller; Michael J Eck
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

6.  Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src.

Authors:  P J Ruest; N Y Shin; T R Polte; X Zhang; S K Hanks
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

7.  The focal adhesion protein paxillin regulates contraction in canine tracheal smooth muscle.

Authors:  Dale D Tang; Ming-Fang Wu; Anabelle M Opazo Saez; Susan J Gunst
Journal:  J Physiol       Date:  2002-07-15       Impact factor: 5.182

8.  Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy.

Authors:  Elizabeth A Grace; Jorge Busciglio
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

9.  Glycogen synthase kinase 3- and extracellular signal-regulated kinase-dependent phosphorylation of paxillin regulates cytoskeletal rearrangement.

Authors:  Xinming Cai; Min Li; Julie Vrana; Michael D Schaller
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

10.  Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.

Authors:  Jodi L Jackson; M Rita I Young
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.